Tharimmune (THAR) announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus associated with primary biliary cholangitis, a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune’s Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency and the U.S. Food and Drug Administration, as well as progress on manufacturing clinical study supply.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THAR:
- Tharimmune initiated with a Buy at Rodman & Renshaw
- Tharimmune presents clinical data on TH104 for chronic pruritus
- Tharimmune granted patent for delivery of molecularly targeted therapeutics
- Tharimmune receives regulatory feedback from EMA for TH104 program
- Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting